A Phase 1, open-label, multicenter, dose-escalation and cohort expansion study of OKN4395, a dual antagonist of EP2 and EP4 prostanoid receptors, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors (INVOKE Trial (OKN-4395-121))

Principal Investigator

Dr Victoria Woodcock

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1010615